Samsung Biologics (KRX:207940) posted first-quarter net income attributable to shareholders of 469.2 billion won, up 42% from 331.3 billion won a year earlier, according to a Friday filing with the Korea Exchange.
The South Korean contract development and manufacturing company's sales jumped 26% year over year to 1.257 trillion won from 999.5 billion won.
Shares of Samsung Biologics rose nearly 1% at market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments